Grazirate OD 500 Tablet ER contains divalproex sodium 500 mg, an extended-release formulation of valproate, indicated primarily for the management of epilepsy, bipolar disorder, and migraine prophylaxis. Divalproex acts by increasing brain concentrations of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, thereby stabilizing neuronal activity and preventing seizure propagation. The extended-release (ER) formulation allows for once-daily dosing, improving patient compliance and maintaining steady plasma drug levels. Grazirate OD 500 is effective in controlling various seizure types, including absence, complex partial, and simple partial seizures. In bipolar disorder, it aids in mood stabilization by reducing manic episodes. For migraine prevention, it decreases the frequency and severity of attacks. The medication should be used under strict medical supervision, with periodic monitoring of liver function tests, platelet counts, and serum valproate levels due to potential hepatotoxicity, thrombocytopenia, and other adverse effects. Common side effects include gastrointestinal disturbances, tremor, weight gain, and sedation. It is contraindicated in patients with hepatic disease, urea cycle disorders, or hypersensitivity to valproate. Dose adjustments may be necessary in special populations such as pediatric or elderly patients. Grazirate OD 500 should be taken consistently with regard to meals to optimize absorption and minimize gastrointestinal discomfort.